Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

NCT04626128 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Neovascular Age-related Macular Degeneration

Interventions

DRUG: CLS-AX
DRUG: Anti-VEGF

Sponsor

Clearside Biomedical, Inc.